Double knockout mice show BASH and PKCδ have different epistatic relationships in B cell maturation and CD40-mediated activation

2006 ◽  
Vol 105 (1) ◽  
pp. 48-54 ◽  
Author(s):  
T NOJIMA ◽  
K HAYASHI ◽  
R GOITSUKA ◽  
K NAKAYAMA ◽  
K NAKAYAMA ◽  
...  
1996 ◽  
Vol 184 (4) ◽  
pp. 1537-1541 ◽  
Author(s):  
C M Snapper ◽  
F R Rosas ◽  
P Zelazowski ◽  
M A Moorman ◽  
M R Kehry ◽  
...  

A number of distinct functional abnormalities have been observed in B cells derived from p50/ NF-kappa B or c-rel knockout mice. RelB, another member of the NF-kappa B/Rel family of transcription factors, is expressed during the latter stages of B cell maturation and can bind to regulatory sites within the Ig heavy chain locus. Therefore, we tested the ability of B cells from relB knockout mice (relB-/-) to proliferate, undergo maturation to IgM secretion, and switch to the expression of downstream Ig isotypes in response to distinct activators including LPS, anti-CD40 mAb or CD40 ligand, and/or dextran anti-IgD antibodies in combination with various cytokines, including IL-4, IL-5, IFN-gamma, and TGF-beta. B cells lacking RelB showed up to 4-fold reductions in DNA synthesis in response to LPS, CD40, and membrane Ig-dependent activation relative to controls. However, relB-/- B cells were comparable to control B cells in their ability to undergo maturation to IgM secretion and switch to the expression of IgG3, IgG1, IgG2b, IgG2a, IgE, and/or IgA under all activation conditions tested. Thus, RelB, like c-Rel and p50/NF-kappa B, plays a role in B cell proliferation. However, in contrast to c-Rel and p50/ NF-kappa B, it is not critically involved in maturation to Ig secretion or expression of Ig isotypes.


2015 ◽  
Vol 3 (2) ◽  
pp. 103-117 ◽  
Author(s):  
Joseph J. Dolence ◽  
Kimberly A. Gwin ◽  
Mariya B. Shapiro ◽  
Fan-Chi Hsu ◽  
Virginia S. Shapiro ◽  
...  

Science ◽  
2019 ◽  
Vol 366 (6470) ◽  
pp. eaay7199 ◽  
Author(s):  
Kevin O. Saunders ◽  
Kevin Wiehe ◽  
Ming Tian ◽  
Priyamvada Acharya ◽  
Todd Bradley ◽  
...  

2021 ◽  
Vol 12 ◽  
pp. 204062072198958
Author(s):  
Larysa Sanchez ◽  
Alexandra Dardac ◽  
Deepu Madduri ◽  
Shambavi Richard ◽  
Joshua Richter

Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from clinical studies of BCMA-targeted therapies with a focus on ADCs and BITEs. Additionally, important differences among the BCMA-targeted treatment modalities and their clinical implications are discussed.


1999 ◽  
Vol 11 (10) ◽  
pp. 1663-1671 ◽  
Author(s):  
Xuejun Shen ◽  
Grazyna Bozek ◽  
Carl A. Pinkert ◽  
Ursula Storb

2010 ◽  
Vol 37 (8) ◽  
pp. 3747-3755 ◽  
Author(s):  
Shaoli Deng ◽  
Tao Yuan ◽  
Xiaoxing Cheng ◽  
Rui Jian ◽  
Jing Jiang

Sign in / Sign up

Export Citation Format

Share Document